文献速递呼吸危重症与机械通气

理解临床与生物学异质性以推进儿童急性呼吸窘迫综合征精准医学

Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome.
PubMed 文献 · Lancet Respir Med · 2022-12-22

儿童急性呼吸窘迫综合征(PARDS)是一种异质性临床综合征,与高死亡率和长期并发症相关。其与成人ARDS在发育阶段、肺成熟度、诱发因素和合并症等方面存在差异,目前无特异性治疗,以支持治疗为主。理解PARDS临床与生物学异质性及与成人ARDS的差异,是开发新型预防和治疗策略及精准医学方法的关键。

要点

  • PARDS是异质性综合征,死亡率和长期并发症发生率高。
  • PARDS与成人ARDS在发育阶段、肺成熟度、诱发因素和合并症上存在差异。
  • 目前无特异性治疗,以支持治疗为主,需识别可从特定通气策略或辅助治疗中获益的患者。

核心结论

  • 理解PARDS的临床与生物学异质性及与成人ARDS的差异,对开发新型预防和治疗策略及精准医学方法至关重要。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • PARDS与成人ARDS的差异涉及发育阶段和肺成熟度随年龄的变化、诱发因素和合并症。
  • 目前无特异性治疗,管理以支持治疗为主,但需要方法识别可从特定通气策略或辅助治疗(如俯卧位通气)中获益的患者。
  • 利用临床、生物标志物和转录组数据及信息学的研究,以及包括在照护点快速识别亚表型和内型的方法,将推动精准医学进展。

临床怎么用

  • 临床应认识PARDS的异质性及与成人ARDS的差异,以支持精准医学导向的照护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Paediatric acute respiratory distress syndrome (PARDS) is a heterogeneous clinical syndrome that is associated with high rates of mortality and long-term morbidity. Factors that distinguish PARDS from adult acute respiratory distress syndrome (ARDS) include changes in developmental stage and lung maturation with age, precipitating factors, and comorbidities. No specific treatment is available for PARDS and management is largely supportive, but methods to identify patients who would benefit from specific ventilation strategies or ancillary treatments, such as prone positioning, are needed. Understanding of the clinical and biological heterogeneity of PARDS, and of differences in clinical features and clinical course, pathobiology, response to treatment, and outcomes between PARDS and adult ARDS, will be key to the development of novel preventive and therapeutic strategies and a precision medicine approach to care. Studies in which clinical, biomarker, and transcriptomic data, as well as informatics, are used to unpack the biological and phenotypic heterogeneity of PARDS, and implementation of methods to better identify patients with PARDS, including methods to rapidly identify subphenotypes and endotypes at the point of care, will drive progress on the path to precision medicine.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Kneyber MCJ, Khemani RG, Bhalla A, et al. Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome. Lancet Respir Med. 2022. PMID: 36566767. doi:10.1016/S2213-2600(22)00483-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。